# A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

> **NCT03920852** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 41 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib cream

## Key facts

- **NCT ID:** NCT03920852
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-30
- **Primary completion:** 2019-12-26
- **Final completion:** 2019-12-26
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03920852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03920852, "A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03920852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*